Healthcare Industry News: Computed Tomography
News Release - June 13, 2007
GE Healthcare Demonstrates Innovative Research Advancements for Next-Generation CT ImagingGE's research pipeline illustrates a continued commitment to developing CT technology that addresses the clinical need for higher spatial resolution and lower dose
SAN FRANCISCO--(HSMN NewsFeed)--GE Healthcare announced today at the Stanford Radiology: 8th Annual International Symposium on Multidetector-Row CT its continued efforts and priority to deliver higher spatial resolution and lower dose to CT imaging. "Our customer's have unanimously told us higher resolution is the priority clinical need," said Gene Saragnese, Vice president and General Manager of GE Healthcare's CT and Molecular Imaging business.
"As leaders in CT, GE continues to focus on developing technologies that provide clinical excellence and outstanding image quality while reducing dose exposure for patients," said Saragnese. "From a CT physics standpoint this is very challenging since higher image quality typically demands higher dose levels, however, increasing dose is not an option. Our research system, installed at Froedtert Memorial Hospital, has demonstrated some very promising results which were highlighted here at the symposium."
Helical Shuttle CT Scans with Expanded Image Coverage of 210mm
GE also demonstrated technology advances in "Helical Shuttle" imaging, using the company's LightSpeed VCT, by generating CT Scans with an expanded image coverage of 210mm on a 40mm detector for both cardiac and liver exams. Helical shuttle scanning continues to hold promise by providing wider image coverage for both dynamic angiography and perfusion studies. 210mm of coverage enables whole organ anatomical and physiological assessment on existing Computed Tomography (CT) technology.
The research was performed at Osaka and Kinki Universities, Japan, by Professor Takamichi Murakami, Chairman, Department of Radiology at Kinki University Hospital.
"The angiographic studies that I obtained using GE's Helical Shuttle provide excellent quality," said Murakami, "and may allow us to investigate in detail the relation between tumors and feeding arteries."
"The underlying technical concept behind Helical Shuttle was to break through the old paradigm that helical scans must be performed at a constant table speed or pitch, relative to the slice thickness," said Brian Duchinsky, General Manager of Global CT at GE Healthcare. "This breakthrough is enabled by an innovative, real-time scan control architecture. Additionally, our engineers have been developing improved reconstruction algorithms that work to produce images acquired with "Helical Shuttle" without artifacts previously associated with varying table speed. These powerful combinations of technology enhancements have the potential to unlock a host of exciting new advanced clinical applications."
Dual Energy May Increase Clinical Utility of Volume CT
The company's volume dual energy imaging research method, when used on GE's existing LightSpeed VCT platform, has been studied over the past year at Keio University, Japan and Duke University, Durham, NC. By building on the foundation of GE's advanced CT platform, the method may allow existing users to expand the clinical utility of volume CT.
At the symposium, Dr. Kuribayashi will present his volume dual energy clinical findings in a session titled "Dual Energy CT of Peripheral Arterial Disease with Single-Source 64-Slice MDCT."
"The research shows promise in improving the detection of enhancing pathology," said Dr. Nelson of Duke University Medical School. "Volume dual energy CT may have the potential for tissue characterization above and beyond simple attenuation or enhancement."
"The LightSpeed VCT ushered in a new era of cardiac imaging by scanning the heart in as few as five seconds," said Saragnese. "Today, GE presents research that builds on the foundation of volume and dual energy imaging to enable new future possibilities for greater clinical utilization of CT."
ABOUT GE HEALTHCARE:
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.
GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE:GE ). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
Source: GE Healthcare
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.